JAMES RIVES: Open Payments
NPI 1740935931 · SPRINGFIELD, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,555 in 119 payments from 16 companies in 2025. Trend: 2023 $2,191 · 2024 $2,222 · 2025 $2,555
Food & beverage: $2,513Education: $42
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 35 | $939 |
| GENZYME CORPORATION | 11 | $256 |
| Novartis Pharmaceuticals Corporation | 13 | $218 |
| GlaxoSmithKline, LLC. | 11 | $177 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $170 |
| CSL Behring | 6 | $161 |
| PFIZER INC. | 6 | $101 |
| ARS Pharmaceuticals Operations, Inc. | 6 | $99 |
| Amgen Inc. | 4 | $81 |
| Pharming Healthcare, Inc. | 4 | $79 |
Products named: FASENRA, BREZTRI, TEZSPIRE, NUCALA, Rhapsido, CIBINQO, NEFFY, Andembry.
Industry payments across MO — which companies pay providers there.
